Parametric Portfolio Associates’s Oric Pharmaceuticals ORIC Stock Holding History

Parametric Portfolio Associates’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$70K	Sell	13,097 -50,131	-79%	-$451K	﹤0.01%	3603
2021 Q4	$929K	Buy	63,228 +7,073	+13%	+$110K	﹤0.01%	2811
2021 Q3	$1.17M	Buy	56,155 +20,574	+58%	+$417K	﹤0.01%	2730
2021 Q2	$629K	Sell	35,581 -2,303	-6%	-$50.5K	﹤0.01%	2986
2021 Q1	$928K	Buy	37,884 +10,190	+37%	+$322K	﹤0.01%	3200
2020 Q4	$937K	Buy	27,694 +3,256	+13%	+$93.4K	﹤0.01%	3082
2020 Q3	$611K	Buy	24,438 +1,000	+4%	+$23.8K	﹤0.01%	3175
2020 Q2	$791K	Buy	+23,438	New	+$748K	﹤0.01%	3047

Other funds holding ORIC

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Parametric Portfolio Associates's ORIC Position: Q1 2022 in Review

Parametric Portfolio Associates reduced its Oric Pharmaceuticals (ORIC) stake by 79% in Q1 2022, selling an estimated $451K and leaving 13,097 shares worth $70K. The position accounts for ﹤0.01% of the portfolio, ranked #3603.

Parametric Portfolio Associates first reported a position in ORIC in Q2 2020 and has held it in 8 quarters since. The position peaked at $1.17M in Q3 2021. 101 funds tracked by Wall St. Rank hold ORIC as of Q1 2022.

Parametric Portfolio Associates held 13,097 shares of Oric Pharmaceuticals worth $70K as of Q1 2022.
Parametric Portfolio Associates sold 50,131 Oric Pharmaceuticals shares in Q1 2022, an estimated $451K.
Oric Pharmaceuticals made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #3603 holding.
Parametric Portfolio Associates first reported a position in Oric Pharmaceuticals in Q2 2020 and has held it in 8 quarters since.
Parametric Portfolio Associates's Oric Pharmaceuticals position peaked at $1.17M in Q3 2021.
101 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.